ExpreS2ion Biotechnologies and Cancer Research UK Enter a Licensing Agreement
News Jun 11, 2013
The stable, non-lytic protein expression platform, which is fully cGMP compatible, will complement the existing capabilities in protein expression at the Protein Purification Facility. The platform will be used to address expression of complex and “challenging” proteins, including Fab fragments and other proteins.
This license is a relevant addition to ExpreS2ion Biotechnologies’ vision of making its production platform available to academic centers of excellence globally, in complement to the Company’s strategy of making S2 one of the standard protein production platforms in the immunotherapy and therapeutic protein segments.
Dr. Charlotte Dyring, CEO of ExpreS2ion Biotechnologies, said: “We are excited to sign this license agreement with the Protein Production Facility of Cancer Research UK, one of the world research centers of excellence for cancer biology. We have in the past used the ExpreS2 protein expression system to enable the advance of cancer projects, and this Research License confirms the relevance of the system in complementing existing protein needs in cancer research.”
Dr. Svend Kjaer, Head of the Protein Purification Facility at the London Research Institute commented: “We are very pleased with the capabilities demonstrated by the ExpreS2 platform, which we have employed for a number of our taxing projects. The technology complements our baculovirus-based protein expression activities perfectly and we look forward to expanding the application range of the technology to other projects involving other promising protein targets implicated in cancer.”
Bioinformatics to Help Understand Intrinsically Disordered ProteinsNews
Over the last several decades, scientists have sequenced 85 million unique proteins, structured and unstructured alike, but still don’t know what the vast majority of these proteins do.READ MORE
Could This Be a "Silver Bullet" for Preventing and Treating Colon Cancer?News
A team of scientists targeted the gene CtBP with a drug known as HIPP (2-hydroxy-imino phenylpyruvic acid) and were able to reduce the development of pre-cancerous polyps by half.READ MORE